IPP Bureau
Zydus receives USFDA’s final approval for Valsartan Tablets
By IPP Bureau - July 24, 2024
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Thyrocare Technologies posts Q1 FY25 consolidated profit at Rs. 24.17 Cr
By IPP Bureau - July 24, 2024
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
Torrent Pharmaceuticals posts Q1 FY25 consolidated PAT at Rs. 457 Cr
By IPP Bureau - July 24, 2024
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr
By IPP Bureau - July 24, 2024
Reported profit after tax declined 19% year-on-year to Rs 76 crores
USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau
By IPP Bureau - July 24, 2024
The inspections concluded with no Form 483 observations or significant critical findings
Poly Medicure posts Q1 FY25 consolidated PAT at Rs. 74.03 Cr
By IPP Bureau - July 23, 2024
Poly Medicure has reported total income of Rs. 401.69 crores during the period ended June 30, 2024
Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr
By IPP Bureau - July 23, 2024
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Biolyst Scientific announced as new brand name to encompass EMS and Azer
By IPP Bureau - July 23, 2024
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Caplin Steriles gets USFDA approval for Ephedrine Sulfate injection USP
By IPP Bureau - July 23, 2024
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
RPG Life Sciences posts Q1 FY25 PAT higher at Rs. 26.76 Cr
By IPP Bureau - July 23, 2024
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Meitheal acquires Contepo from Nabriva Therapeutics to expand specialty biopharmaceuticals portfolio
By IPP Bureau - July 23, 2024
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC
By IPP Bureau - July 23, 2024
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Industry hails Union Budget 2024-25
By IPP Bureau - July 23, 2024
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
